Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

361563 GSK-3 Inhibitor XXII, Compound A - Calbiochem

361563
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Tabla espec. clave

Empirical Formula
C₁₇H₂₃N₅O₃

Products

Número de referenciaEmbalaje Cant./Env.
361563-5MG 5 mg
Description
OverviewA cell-permeable pyrazolopyridine compound that acts as a potent inhibitor against both GSK-3α and GSK-3β (IC50 = 2.3 and 2 nM, respectively, in the presence of 0.5 µM of ATP) with much reduced or little activity toward a panel of 27 other commonly studied kinases. Shown to selectively inhibit the phosphorylation of cellular tau on GSK-specific serine/threonine residues, but not those targeted by non-GSK kinases, both in primary rat cortical neuron cultures (up to 30 µM) in vitro and in mice (up to 26 mg/kg/day p.o.) in vivo. Chronic oral treatment of compound A is also reported to significantly reduce insoluble tau aggregate formation by up to 70% (26 mg/kg/day p.o.) in brain tissues from JNPL3 mice expressing human 4R0N tau with a FTDP-17 (P301L) mutation.
Catalogue Number361563
Brand Family Calbiochem®
Synonyms6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide
References
ReferencesUno. Y., et al. 2009. Brain Res. 1296, 148.
Product Information
FormGreen-grey solid
Hill FormulaC₁₇H₂₃N₅O₃
Chemical formulaC₁₇H₂₃N₅O₃
Structure formula ImageStructure formula Image
Applications
Biological Information
Purity≥95% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications

Documentation

GSK-3 Inhibitor XXII, Compound A - Calbiochem Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

GSK-3 Inhibitor XXII, Compound A - Calbiochem Certificados de análisis

CargoNúmero de lote
361563

Referencias bibliográficas

Visión general referencias
Uno. Y., et al. 2009. Brain Res. 1296, 148.
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision28-February-2011 RFH
Synonyms6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide
DescriptionA cell-permeable pyrazolopyridine compound that acts as a potent inhibitor against both GSK-3α and GSK-3β (IC50 = 2.3 and 2 nM, respectively, in the presence of 0.5 µM of ATP) with much reduced or little activity toward a panel of 27 other commonly studied kinases. Shown to selectively inhibit the phosphorylation of cellular tau on GSK-specific serine/threonine residues, but not those targeted by non-GSK kinases, both in primary rat cortical neuron cultures (up to 30 µM) in vitro and in mice (up to 26 mg/kg/day p.o.) in vivo. Chronic oral treatment of compound A is also reported to significantly reduce insoluble tau aggregate formation by up to 70% (26 mg/kg/day p.o.) in brain tissues from JNPL3 mice expressing human 4R0N tau with a FTDP-17 (P301L) mutation.
FormGreen-grey solid
Intert gas (Yes/No) Packaged under inert gas
Chemical formulaC₁₇H₂₃N₅O₃
Structure formulaStructure formula
Purity≥95% by HPLC
SolubilityDMSO (50 mg/ml)
Storage +2°C to +8°C
Protect from light
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Standard Handling
ReferencesUno. Y., et al. 2009. Brain Res. 1296, 148.